Ferric Citrate Tablet Franchise in Ahmedabad

Feryskol 210 mg Tablet Supplier in Mumbai

Iron Supplement Tablet Distributor in Delhi

Ferric Citrate Tablet Manufacturer in Bangalore

Anemia & CKD Tablet Stockist in Hyderabad
Ferric Citrate Tablet Exporter in Chandigarh

Home/Products /ferric-citrate-210mg-tablet

Feryskol 210 Tablet

Composition : Ferric Citrate (210mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹1/-

Feryskol 210 Tablet contains Ferric Citrate 210 mg, a highly bioavailable iron salt and phosphate binder, widely used in iron deficiency anemia and chronic kidney disease (CKD) patients requiring phosphate management.

This tablet works by supplying elemental iron to replenish iron stores while binding dietary phosphate, helping maintain optimal mineral balance in CKD patients. It ensures improved hemoglobin levels and reduced phosphate burden, making it an effective choice for both renal and hematology clinical protocols.

Clinically, Feryskol 210 Tablet is used in patients with chronic kidney disease on dialysis, iron deficiency anemia, or related conditions, where careful monitoring of iron and phosphate levels is critical for safety and efficacy.

The tablet provides consistent dosing, high absorption, and reliable therapeutic outcomes, making it suitable for hospitals, nephrology clinics, dialysis centers, and specialty pharmacies that require a dependable iron supplement and phosphate management therapy.

Read More

About the Product

Feryskol 210 Tablet contains Ferric Citrate 210 mg, a highly bioavailable iron salt and phosphate binder, widely used in iron deficiency anemia and chronic kidney disease (CKD) patients requiring phosphate management.

This tablet works by supplying elemental iron to replenish iron stores while binding dietary phosphate, helping maintain optimal mineral balance in CKD patients. It ensures improved hemoglobin levels and reduced phosphate burden, making it an effective choice for both renal and hematology clinical protocols.

Clinically, Feryskol 210 Tablet is used in patients with chronic kidney disease on dialysis, iron deficiency anemia, or related conditions, where careful monitoring of iron and phosphate levels is critical for safety and efficacy.

The tablet provides consistent dosing, high absorption, and reliable therapeutic outcomes, making it suitable for hospitals, nephrology clinics, dialysis centers, and specialty pharmacies that require a dependable iron supplement and phosphate management therapy.

Common side effects may include mild gastrointestinal discomfort, constipation, diarrhea, nausea, or dark stools. Rarely, allergic reactions, severe constipation, or iron overload may occur.

Feryskol 210 Tablet is indicated for the management of hyperphosphatemia in patients with chronic kidney disease and for treatment of iron deficiency anemia in those requiring supplemental iron. It helps maintain healthy phosphate levels and improve hemoglobin levels.

Use Feryskol 210 Tablet strictly under medical supervision. Take it with meals as directed by your healthcare provider. Inform your doctor of any history of hypercalcemia, iron overload, gastrointestinal disorders, or kidney disease. Contact your physician immediately if you experience severe abdominal pain, persistent constipation, or unusual allergic reactions.

Store in a cool, dry place below 25°C. Protect from moisture and direct sunlight. Keep out of reach of children. Do not use beyond the expiry date.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation